Retrospective Study Collecting Clinical and Tissue Data for Precision Research in Colorectal Cancer

What this Trial Is About

Researchers are conducting a retrospective study called ALFAOMEGA-RETR to collect clinical, imaging, and biological data from patients diagnosed with colorectal cancer CRC. The study aims to support precision research by analyzing these data to develop a new classification of CRC based on evolutionary patterns and to explore innovative biomarker-driven treatment approaches. This effort is part of a larger multi-institutional research program focusing on colorectal cancer heterogeneity. The study involves gathering data and samples from at least 500 CRC patients across various disease stages. These include clinical records, imaging scans such as CT, MRI, and PET, and biological materials like formalin-fixed paraffin-embedded tissue from surgeries or biopsies, as well as frozen samples including blood, plasma, stool, and others. This protocol operates retrospectively and collects information from patients who are no longer reachable for consent due to death or loss to follow-up. Participants themselves are not actively involved, as the study relies on previously collected data and archived samples. Researchers will analyze the number of CRC cases recruited retrospectively over six months. The collected data will support experimental research to deepen understanding of CRC and assist in developing targeted therapies. The study is observational and will continue through December 2026.

A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)